Dr. Devarakonda on Biomarkers Beyond PD-L1 in NSCLC

Siddhartha Devarakonda, MD
Published: Thursday, May 11, 2017



Siddhartha Devarakonda, MD, a senior fellow at Washington University School of Medicine in St. Louis, discusses biomarkers beyond PD-L1 being explored in patients with non–small cell lung cancer (NSCLC).

A newer target that is gaining great interest in the field is the MET exon 14 skipping mutation, as research suggests that this is a target with many alterations. Encouraging responses are observed with crizotinib (Xalkori) in these patients. Although it is not approved in lung cancer, cabozantinib (Cabometyx) is a drug with potential.  

Secondly, there are good clinical trial data showing that BRAF V600E is a targetable abnormality, as well. Both dabrafenib (Tafinlar) and trametinib (Mekinist) basket trials and vemurafenib (Zelboraf) have also been linked with responses in lung cancer that had the V600E mutation. Finally, the NTRK1 mutation is being studied in the STARTRK trial with entrectinib.


Siddhartha Devarakonda, MD, a senior fellow at Washington University School of Medicine in St. Louis, discusses biomarkers beyond PD-L1 being explored in patients with non–small cell lung cancer (NSCLC).

A newer target that is gaining great interest in the field is the MET exon 14 skipping mutation, as research suggests that this is a target with many alterations. Encouraging responses are observed with crizotinib (Xalkori) in these patients. Although it is not approved in lung cancer, cabozantinib (Cabometyx) is a drug with potential.  

Secondly, there are good clinical trial data showing that BRAF V600E is a targetable abnormality, as well. Both dabrafenib (Tafinlar) and trametinib (Mekinist) basket trials and vemurafenib (Zelboraf) have also been linked with responses in lung cancer that had the V600E mutation. Finally, the NTRK1 mutation is being studied in the STARTRK trial with entrectinib.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x